WUXI BIO (02269): Miao Jingwen appointed as non-executive director.
Wu Yibing, Ph.D., has resigned as of November 20, 2024, in an announcement from WuXi Biologics (02269).
WUXI BIO (02269) announces that, effective from November 20, 2024, Dr. Wu Yibing has resigned as a non-executive director and member of the Board's decision-making committee to dedicate more time to other personal matters. Ms. Miao Jingwen has been appointed as a non-executive director and member of the decision-making committee.
Related Articles
JNBY (03306) plans to offer a discount of approximately 9.01% for the placement of 14.535 million shares. The net proceeds are estimated to be around HK$270 million.
OSL GROUP (00863) issues profit warning, expecting a net loss of approximately HK$370 million to HK$430 million for the fiscal year 2025, turning from a profit to a loss compared to the previous year.
BRAINAURORA-B(06681) plans to discount about 12.09% of the existing and new shares for a net fundraising of about 5.01 billion Hong Kong dollars.
JNBY (03306) plans to offer a discount of approximately 9.01% for the placement of 14.535 million shares. The net proceeds are estimated to be around HK$270 million.
OSL GROUP (00863) issues profit warning, expecting a net loss of approximately HK$370 million to HK$430 million for the fiscal year 2025, turning from a profit to a loss compared to the previous year.
BRAINAURORA-B(06681) plans to discount about 12.09% of the existing and new shares for a net fundraising of about 5.01 billion Hong Kong dollars.
RECOMMEND
Paul Chan Says Hong Kong Has Licensed 11 Virtual Asset Exchanges, Stablecoin Licenses Expected Later This Year
22/01/2026
Ministry Of Finance And Other Departments Introduce Comprehensive Fiscal And Financial Policies To Boost Domestic Demand
22/01/2026
Capital Migration: Five Years On, An In‑Depth Analysis Of China’s 11 High‑Growth Venture Capital Tracks In 2025
22/01/2026
